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Abstract The regulation of the activity of CaMKII by PP-1
and PP-2A, as well as the role of this protein kinase in the
phosphorylation of tau protein in forebrain were investigated.
The treatment of metabolically active rat brain slices with 1.0
WM okadaic acid (OA) inhibited V65% of PP-2A and had no
significant effect on PP-1 in the 16 000Ug tissue extract.
Calyculin A (CL-A), 0.1 WM under the same conditions, inhibited
V50% of PP-1 and V20% of PP-2A activities. In contrast, a
mixture of OA and CL-A practically completely inhibited both
PP-2A and PP-1 activities. The inhibition of the two phosphatase
activities or PP-2A alone resulted in an V2-fold increase in
CaMKII activity and anV8-fold increase in the phosphorylation
of tau at Ser 262/356 in 60 min. Treatment of the brain slices
with KN-62, an inhibitor of the autophosphorylation of CaMKII
at Thr 286/287, produced V60% inhibition in CaMKII activity
and no significant effect on tau phosphorylation at Ser 262/356.
The KN-62-treated brain slices when further treated with OA
and CL-A did not show any change in CaMKII activity. In vitro,
both PP-2A and PP-1 dephosphorylated tau at Ser 262/356 that
was phosphorylated with purified CaMKII. These studies suggest
(i) that in mammalian forebrain the cytosolic CaMKII activity is
regulated mainly by PP-2A, (ii) that CaMKII is the major tau
Ser 262/356 kinase in brain, and (iii) that a decrease in PP-2A/
PP-1 activities in the brain leads to hyperphosphorylation of tau
not only by inhibition of its dephosphorylation but also by
promoting the CaMKII activity. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Type II Ca2/calmodulin-dependent protein kinase (CaM-
KII) is a key regulatory enzyme and a number of studies have
been carried out to understand its functions in the brain. It is
the most abundant of the known brain Ca2-regulated protein
kinases [2], constituting about 1% of total brain protein [3]. It
is expressed primarily in neurons and had been found in sev-
eral subcellular pools including cytosolic, membrane, cytoskel-
etal and nuclear fractions [4]. Rat brain CaMKII is an oligo-
meric enzyme with a native molecular weight of about 540 000
and ¢ve subunits (K, L/LP, Q, N) have now been identi¢ed using
molecular techniques. The K and L subunits are predomi-
nantly expressed in the nervous system. The K subunit pre-
dominates in the forebrain [3,4], while the L and the LP sub-
units predominate in the cerebellum.
Several studies have focused on the characterization of the
structural and regulatory properties of the CaMKII. In the
absence of Ca2/calmodulin (CaM), CaMKII is essentially
inactive toward exogenous substrates due to interaction of
an autoinhibitory domain (residues 281^302) with the cata-
lytic domain (residues 1^260) [5,6]. Ca2/CaM binding to
residues 296^309 [6] disrupts this inhibitory interaction.
Therefore, in the presence of Ca2/CaM the kinase can phos-
phorylate exogenous substrates. CaMKII is known to be
regulated by autophosphorylation at multiple sites with pro-
found e¡ects on its regulatory properties. In the presence of
Ca2/CaM, Thr 286/287 (K/L subunits, respectively) are the
major sites of autophosphorylation (e.g. [7]). This autophos-
phorylation results in the conversion of the kinase to a Ca2-
independent form (e.g. [7,8]), full activation of the total activ-
ity [9^11], and trapping of Ca2/CaM [12]. Removal of Ca2/
CaM from the autophosphorylated kinase stimulates Ca2-
independent autophosphorylation at Thr 305 and/or Thr
306, as well as Ser 314 [13,14]. This Ca2-independent auto-
phosphorylation inhibits consequent Ca2/CaM binding to
CaMKII and results in a decrease in the activity of the kinase
[13^15]. Therefore, the identi¢cation of protein phosphatases
that dephosphorylate CaMKII is of great interest to under-
stand the regulation of its activity. It has so far been reported
that protein phosphatase-1 (PP-1) [16], protein phosphatase-
2A (PP-2A) [7,17,18], and PP-2C [19] dephosphorylate Thr
286 in vitro and that the dephosphorylation is catalyzed by
distinct phosphatases in distinct subcellular compartments
[20]. Thr 306 was shown to be dephosphorylated by PP-2A
[15]. However, which protein phosphatases regulate CaMKII
in the brain was not reported.
CaMKII phosphorylates a broad range of substrate pro-
teins including the microtubule-associated protein tau
[21,22]. In Alzheimer disease (AD), one of the hallmark neu-
ropathological lesions is the accumulation of paired helical
¢laments (PHFs) of which the major protein subunit is the
abnormally hyperphosphorylated tau [23,24]. Among 21 sites
identi¢ed in PHF tau, one critical site is Ser 262, the only site
located within the microtubule binding domain of tau. Phos-
phorylation of tau at this site reduces the ability of tau to bind
to microtubules and to promote their assembly [25,26].
Tau can be phosphorylated at Ser 262/356 in vitro by CaM-
KII [26], protein kinase A (PKA) [27,28], Mark110 kinase [29],
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glycogen synthase kinase-3 (GSK-3) [30], casein kinase-1 [26],
protein kinase C [26] and phosphorylase kinase [31]. In a
previous study, we have shown that the phosphorylation of
tau at Ser 262/356 in metabolically active rat brain slices is
positively and negatively modulated in the presence of CaM-
KII activator, bradykinin, and inhibitor, KN-62, respectively
[32]. In the present study we describe the role of PP-2A and
PP-1 in the regulation of the activity of CaMKII and the
phosphorylation of tau at Ser 262/356 by this protein kinase
in rat forebrain cytosol.
2. Materials and methods
2.1. Preparation and treatment of rat brain slices with phosphatase
inhibitors
Female Wistar rats, 3 months old, were killed by a lethal dose of
Nembutal (intraperitoneal injection of 75 mg Nembutal per kg body
weight) followed by heart puncture. The brain was rapidly removed
and cooled in oxygenated (95% O2/5% CO2) arti¢cial cerebrospinal
£uid (aCSF) containing 150 mM NaCl, 2 mM CaCl2, 1.2 mM
MgSO4, 0.5 mM KH2PO4, 1.5 mM K2HPO4 and 10 mM glucose
at pH 7.4. The cerebellum and brain stem were discarded, the fore-
brain was sliced vertically and cross-sectionally at every 500 Wm using
a Mcllwain Tissue Chopper (Brinkman Instruments). The slices were
washed two times with aCSF and then incubated at 35‡C in oxygen-
ated aCSF either alone or in the presence of phosphatase and or
kinase inhibitors as described in Section 3. The incubation medium
was continuously oxygenated. After di¡erent periods of time the brain
slices were removed, washed two times and homogenized at 4‡C using
a Te£on-glass homogenizer in 50 mM Tris^HCl, pH 7.0, containing
10 mM L-mercaptoethanol (L-ME) and a cocktail of protease inhib-
itors (1 mM EDTA, 0.1 mM phenylmethyl sulfonyl £uoride (PMSF),
2.0 mM benzamidine and 2.0 Wg/ml each of aprotinin, leupeptin and
pepstatin). The homogenate was then divided into two parts, one was
centrifuged at 16 000Ug for 20 min and the supernatant was used to
assay activities of PP-2A and PP-1. The rest of the homogenate was
diluted 1:1 with a phosphatase inhibitor cocktail (20 mM L-glycero-
phosphate, 2.0 mM Na3VO4 and 100 mM NaF, pH 7.0) and either
used for Western blots, or centrifuged at 16 000Ug for 20 min and the
resulting supernatant used to determine the activities of CaMKII and
cyclic AMP-dependent protein kinase (PKA).
2.2. Western blots
[125I] Western blots of brain homogenate were developed as de-
scribed previously [33]. To determine the phosphorylation state of
tau protein, the blots were probed with the following tau antibodies:
monoclonal antibodies (mAbs) PHF1 (1:200) to P-Ser 396/404 [34],
12E8 (1:500) to P-Ser 262/356 [35], M4 (1:2000) to P-Thr 231/Ser 235
[36], Tau-1 (1:25 000) to Ser 195/198/199/202 [23,37], or polyclonal
antibodies (pAbs) R145 (1:3000) to P-Ser 422 [38] and 92e (1:5000)
to total tau [39].
2.3. Protein phosphatase assays
Activities of PP-2A and PP-1 were assayed towards [32P]phos-
phorylase a as a substrate as we described previously [33,40]. The
phosphatase activity was assayed in 50 mM Tris, pH 7.0, 10 mM
L-ME, 0.1 mM EGTA, 7.5 mM ca¡eine, 2 mg/ml [32P]phosphorylase
and 0.1 mg/ml brain extract. A PP-1 speci¢c inhibitor, phosphorylated
inhibitor-1 [41], was included in the assays for PP-2A activity. PP-1
activity was calculated by subtracting the PP-2A activity from the
total phosphatase activity (PP-1+PP-2A) assayed in the absence of
inhibitor-1.
2.4. Protein kinase assay
CaMKII activity was measured in 25 Wl of bu¡er containing 60 mM
HEPES, pH 7.5, 10 mM MgCl2, 2.0 mM CaCl2, 10 mM L-ME, 10
mM EGTA, 10 Wg/ml calmodulin (Sigma, St. Louis, MO, USA), 20
WM Syntide 2 (Sigma, St. Louis, MO, USA), 0.2 mg/ml brain extract
and 200 WM [Q-32P]ATP. The reaction was initiated by adding
[Q-32P]ATP. After incubation for 10 min at 30‡C, 25 Wl of 300 mM
phosphoric acid was added to terminate the reaction and 10 Wl of
sample was spotted on to phosphocellulose membrane. The mem-
brane was then washed three times in 75 mM phosphoric acid to
remove non-protein incorporated 32P, dried and counted by Cerenkov
radiation. The activity of PKA was determined as above except the
reaction mixture contained 0.05 mg/ml brain extract, 70 mM
NaHPO4, pH 6.8, 14 mM MgCl2, 1.4 mM EGTA, 5.0 WM cyclic
AMP (Sigma, St. Louis, MO, USA), 30 WM malantide (Sigma, St.
Louis, MO, USA) and 200 WM [Q-32P]ATP.
2.5. In vitro phosphorylation of tau410 by CaMKII followed by
dephosphorylation by PP-2A or PP-1
The human tau clone 39 which encodes tau isoform 3L (tau410) was
subcloned in Escherichia coli and the recombinant protein was puri-
¢ed from cell extracts as described previously [42]. Tau410 was phos-
phorylated at 30‡C in a reaction mixture containing 1.6 Wg/ml puri¢ed
CaMKII (Calbiochem, San Diego, CA, USA), 0.4 mg/ml tau410, 5.0
mM MgCl2, 2.0 mM CaCl2, 10 mM L-ME, 60 mM HEPES, pH 7.5,
1.0 mM PMSF, 0.1 mg/ml bovine serum albumin, 10 Wg/ml of each
leupeptin, pepstatin, aprotinin, 10 Wg/ml calmodulin and 0.1 mM
ATP. The reaction was initiated by addition of ATP. After 60 min
of incubation, the reaction mixture was heated for 5 min at 95‡C and
centrifuged at 16 000Ug for 5 min. Tau, which is heat stable under
these conditions, was then removed as supernatant and aliquoted. The
dephosphorylation of tau410 was conducted by adding to 30 Wl of
supernatant either the catalytic subunit of PP-2A (¢nal concentration
0.9 Wg/ml) or PP-1 (¢nal concentration 0.45 Wg/ml), both puri¢ed from
bovine brain according to the method of Cohen et al. [43]. After 2 h
of incubation at 30‡C the reaction was stopped by addition of SDS^
PAGE sample bu¡er and 10 ng of tau410 per lane was then loaded for
Western blots.
3. Results
3.1. Okadaic acid (OA) and calyculin A (CL-A) inhibit
PP-2A and PP-1 in rat brain slices
Unlike in vitro and in cultured cells where OA can com-
pletely inhibit both PP-2A and PP-1 activities [38,44], in brain
slices only up to V70% of PP-2A and insigni¢cant PP-1 ac-
tivities are inhibited [40]. Since OA and CL-A are chemically
quite di¡erent and probably act on di¡erent sites of the phos-
phatases, we investigated the inhibition of the activities of PP-
2A and PP-1 by OA and CL-A separately and in combina-
tion. OA (1.0 WM) inhibited V65% of PP-2A activity while
PP-1 activity remained practically unchanged (Table 1). Dur-
ing 1 h of treatment of the brain slices with 0.1 WM CL-A, a
potent inhibitor of both PP-1 and PP-2A, V50% of PP-1 and
V20% of PP-2A activities were inhibited. Interestingly, when
rat brain slices were treated with both CL-A (0.1 WM) and OA
(1.0 WM), neither PP-2A nor PP-1 activity could be detected.
Thus, a combination of protein phosphatase inhibitors proved
Table 1
Inhibition of PP-2A and PP-1 by OA and CL-A in rat brain slices
Treatment Protein phosphatase activity (%)
PP-2A PP-1
30 min 60 min 30 min 60 min
aCSF 100 100 100 100
OA (1.0 WM) 34 þ 2 37 þ 2 91 þ 2 89 þ 2
CL-A (0.1 WM) 88 þ 3 78 þ 3 44 þ 2 52 þ 3
OA and CL-A ND ND ND ND
Rat brain slices were treated with 1.0 WM OA, 0.1 WM CL-A or
both for 30 or 60 min. The tissue was then homogenized and
16 000Ug extract used for assaying the activities of PP-2A and
PP-1. Protein phosphatase activity was determined using [32P]phos-
phorylase a as a substrate. Data are expressed as a percentage of
the phosphatase activity detected in aCSF-treated rat brain slices.
Means þ S.D. of three experiments are presented. ND, not detect-
able.
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to be a very useful approach to achieve a complete inhibition
of both PP-2A and PP-1 in brain.
3.2. OA and CL-A stimulate CaMKII activity
In vitro studies have suggested that PP-2A can have both
inhibitory and stimulatory e¡ects on CaMKII because it can
dephosphorylate the kinase at Thr 286/287 [45] and at Thr
305/306 [15] which inhibits and stimulates its activity, respec-
tively. CaMKII in post synaptic densities can be dephosphor-
ylated by PP-1 at Thr 236/287 [45]. Thus, from in vitro studies
it is di⁄cult to predict the e¡ect of the activities of PP-2A and
PP-1 on CaMKII in vivo. In the present study we investigated
the regulation of the cytosolic CaMKII activity by PP-1 and
PP-2A in rat brain.
Rat brain slices were treated with a mixture of 1.0 WM OA
and 0.1 WM CL-A in aCSF. At di¡erent incubation times the
slices were removed, homogenized and 16 000Ug extract pre-
pared from them. The activities of CaMKII and PKA were
determined in the extract. The activity of cytosolic CaMKII
was markedly and speci¢cally increased after treatment of the
brain slices with OA plus CL-A (Fig. 1A), whereas no signi¢-
cant change in PKA activity was observed (Fig. 1B). These
studies suggested that in rat forebrain PP-2A or PP-1 or both
might regulate CaMKII activity by dephosphorylation of the
kinase at Thr 286/287. In rat brain slices where both PP-2A
and PP-1 activities were totally inhibited by OA plus CL-A,
CaMKII activity increased up to 220% after 10 min of treat-
ment and slightly decreased to V170% by 60 min (Fig. 1A).
This decrease in CaMKII activity might be the result of an
unchecked autophosphorylation of the kinase at Thr 305/306
due to complete inhibition of PP-2A [15], or a slow dephos-
phorylation of CaMKII at Thr 286/287 by other protein phos-
phatases such as PP-2C or CaMKII phosphatase, an OA and
CL-A insensitive phosphatase [19,46].
3.3. OA and CL-A increase tau phosphorylation at Ser 262/356
The state of tau phosphorylation was investigated using a
battery of phosphorylation-dependent antibodies as described
in Section 2. The treatment of brain slices with OA plus CL-A
resulted in hyperphosphorylation of tau at Ser 262/356 as
determined with the mAb 12E8 (Fig. 1C,D). The level of total
tau as determined by [125I] Western blots developed with pAb
Fig. 1. OA plus CL-A stimulate CaMKII activity and increase phosphorylation of tau at Ser 262/356 in rat forebrain. Rat brain slices were
treated with aCSF alone or in the presence of 1.0 WM OA and 0.1 WM CL-A for up to 60 min, and then homogenized. The tissue homogenate
was either used for Western blots or centrifuged at 16 000Ug for 20 min and the extract used for the kinase assays as described in Section 2.
The activities of (A) CaMKII and (B) PKA of inhibitors-treated samples (black bars) were expressed as the percentage of the activities of the
control samples (open bars) treated with aCSF alone for the same period of incubation. OA/CL-A stimulated the activity of CaMKII by V2-
fold in rat brain slices whereas the PKA activity was not signi¢cantly a¡ected. (C) Western blots were developed with the mAb 12E8 (1:500)
which recognizes tau phosphorylated at Ser 262/356 (upper panel; 10 Wg protein per lane), and the pAb 92e (1:5000) directed against total tau
(lower panel; 5 Wg protein per lane). Treatment of rat brain slices with OA/CL-A induced phosphorylation of tau at Ser 262/356. Hyperphos-
phorylation of tau at Ser 262/356 was observed at 10 min and increased until 60 min of incubation with OA/CL-A. (D) Western blots such as
in C were scanned and the immunoreactivity at Ser 262/356 obtained with the mAb 12E8 was normalized against the level of total tau detected
with the pAb 92e. Data are expressed as 12E8/92e immunoreactivity. The level of phosphorylation at Ser 262/356 in OA/CL-A-treated samples
(black bars) was V2-fold increased compared to the control (open bars) after 10 min of incubation. Hyperphosphorylation was V8-fold higher
in rat brain slices treated for 60 min with OA/CL-A than in control. Data in A, B, and D are presented as mean þ S.D. obtained from at least
three experiments. *P6 0.05; **P6 0.01.
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tau 92e was not a¡ected by OA plus CL-A treatment. The
increase of tau phosphorylation at Ser 262/356 was detectable
as early as at 10 min of treatment and by 60 min was V8-fold
higher than in the aCSF-treated control brain slices (Fig. 1D).
A lack of quantitative correlation between the increase in the
CaMKII activity and increase in the phosphorylation of tau
suggested (i) that the dephosphorylation of tau at Ser 262/356
might be regulated by PP-2A/PP-1 and (ii) that the maximal
inhibition of these phosphatases in the brain slices probably
occurred between 10 and 20 min after the OA/CL-A treatment
(compare Fig. 1A with Fig. 1D). No signi¢cant change in the
phosphorylation of tau at Tau-1 (Ser 195/198/199/202), M4
(Thr 231/Ser 235), PHF1 (Ser 396/404) or R145 (Ser 422) sites
was observed (data not shown).
3.4. CaMKII phosphorylates tau at Ser 262/356 in brain
To elucidate whether activation of CaMKII activity was
responsible for the elevated level of phosphorylation at Ser
262/356, rat brain slices were incubated with KN-62, a selec-
tive inhibitor of CaMKII. CaMKII activity was inhibited by
V60% in rat brain slices treated with KN-62 for 60 min as
compared to aCSF-treated tissue (Fig. 2A, lanes 1 and 2). The
addition of OA and CL-A for 30 more min into the incuba-
tion medium did not stimulate CaMKII activity (lane 5); the
level of activity remained lower than the control (compare
lane 5 with lanes 1 and 4). Whereas aCSF pretreated rat brain
slices showed an increase in CaMKII activity when OA and
CL-A were added to the medium (compare lane 6 with lanes 4
and 5). This increase in CaMKII activity was, however, small-
er than that observed when the brain slices were not pre-
treated with aCSF for 1 h prior to the OA/CL-A treatment
(compare Fig. 2A, lane 6 with lane 3, and with Fig. 1A, 30
min). A likely cause of this di¡erence is that during 60 min
incubation of the brain slices in aCSF, there was V60% de-
crease in CaMKII activity (data not shown). This decrease in
the kinase activity in the slices might be due to a gradual loss
of the intracellular calcium homeostasis, resulting in a shift
from the kinase switch on/autophosphorylation at Thr 286/
287 to switch o¡/autophosphorylation at Thr 305/306 posi-
tion.
Corresponding to the CaMKII activity, the phosphoryla-
tion of tau at Ser 262/356 was increased in the brain slices
treated with aCSF for 60 min and then with OA plus CL-A
for 30 min, but not in the tissue which was treated ¢rst with
KN-62 and then with the phosphatase inhibitors (Fig. 2B,
compare lanes 4, 5 and 6). Taken altogether, these results
suggest that the stimulation of CaMKII is responsible for
the hyperphosphorylation of tau observed at Ser 262/356 in
rat forebrain. The phosphorylation of tau at Ser 262/356 by
CaMKII was also con¢rmed in vitro. Recombinant human
tau410 was phosphorylated at Ser 262/356 by puri¢ed CaMKII
as determined by Western blots developed with tau antibody
12E8; the phosphorylation of tau by CaMKII also induced a
marked mobility shift on SDS^PAGE (Fig. 2C). Tau410 phos-
phorylated at Ser 262/356 by CaMKII could be dephosphor-
ylated in vitro both by PP-2A and PP-1. This dephosphory-
lation of tau reversed its mobility shift which was induced by
phosphorylation with CaMKII (Fig. 2C). The mobility shift
might not be solely due to phosphorylation of Ser 262/356.
3.5. CaMKII is regulated by phosphorylation
Rat brain slices were incubated with OA and CL-A with or
without KN-62. CaMKII activity was monitored at di¡erent
time points (Fig. 3A). The activity of CaMKII was stimulated
after treatment with both OA and CL-A. The maximum ac-
tivity which was observed at 10 min slowly and gradually
decreased with time up to 60 min studied. The CaMKII ac-
tivity also decreased in the brain slices incubated in aCSF
alone; at 20, 30, and 60 min, the kinase activity was about
80, 60 and 40%, respectively, of that at 10 min incubation
Fig. 2. KN-62 inhibits CaMKII activity and phosphorylation of tau
at Ser 262/356 in rat forebrain. (A) CaMKII activity and (B) phos-
phorylation of tau at Ser 262/356 determined as in Fig. 1. The brain
slices were treated as follows: 1, aCSF for 60 min; 2, KN-62 (10
WM) for 60 min; 3, 1.0 WM OA plus 0.1 WM CL-A for 60 min;
4, aCSF for 90 min; 5, KN-62 (10 WM) for 60 min and followed by
1.0 WM OA plus 0.1 WM CL-A for 30 min; and 6, aCSF for 60
min, followed by 1.0 WM OA and 0.1 WM CL-A for 30 min. Not
shown in this ¢gure there was a V60% decrease in CaMKII activity
during 60 min incubation in aCSF-treated brain slices. Treatment of
rat brain slices with OA plus CL-A for 60 min (bar #3) increased
CaMKII activity by about 2-fold. KN-62 inhibited V60% of CaM-
KII (bar #2) and the inhibition was maintained even after treatment
with OA plus calyculin for 30 more min (bar #5). The brain slices
incubated in aCSF for 60 min and then further treated with OA
plus CL-A for 30 min, however, resulted in an increase in CaMKII
activity (bar #6). Signi¢cant phosphorylation of tau at Ser 262/356
was detected only in brain slices treated with OA and CL-A (bars
#3 and #6). Data are presented as mean þ S.D. of three experi-
ments. *P6 0.05, **P6 0.01 as compared with bars #1 and #4.
(C) Tau410 was phosphorylated with CaMKII followed by dephos-
phorylation with PP-2A or PP-1. Phosphorylation of recombinant
human tau410 was determined by Western blots developed with the
mAb 12E8 (upper panel; 10 ng tau410 per lane) and the pAb 92e
(lower panel; 10 ng tau410 per lane); recombinant human tau410
(lane 1), phosphorylated by puri¢ed CaMKII (lane 2), phosphory-
lated by CaMKII and then dephosphorylated by PP-2A (lane 3),
and phosphorylated by CaMKII and then dephosphorylated by
PP-1 (lane 4). Phosphorylation of recombinant tau410 induced a mo-
bility shift (lane 2). CaMKII-phosphorylated human tau410 was de-
phosphorylated by both PP-2A and PP-1. Note that after dephos-
phorylation the mobility shift was abolished.
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(data not shown). The presence of KN-62, along with OA and
CL-A, did not inhibit CaMKII activity for the ¢rst 30 min; at
60 min a small decrease in the KN-62-treated brain slices was,
however, observed (Fig. 3A). KN-62 is known to inhibit
CaMKII activity by competing with calmodulin [47], which
means KN-62 inhibits not only substrate phosphorylation but
also autophosphorylation of CaMKII, i.e. the activation of
the enzyme. However KN-62 does not inhibit the activity of
autophosphorylated CaMKII [47]. Therefore, the lack of in-
hibition of the CaMKII activity observed in rat brain slices
during the ¢rst 30 min might be due to the fact that the
majority of the enzyme was probably in autophosphorylated
form. It has been shown in vitro that autophosphorylation of
CaMKII in the presence of Ca2/CaM is an extremely process
[11,17]. To regulate the kinase activity the dephosphorylation
of CaMKII might also be rapid in the cell. Thus, KN-62 did
not have any e¡ect on CaMKII probably because of its rapid
autophosphorylation at Thr 286/287, and because the inhibi-
tion of protein phosphatases PP-2A and PP-1 maintained the
autophosphorylated status of CaMKII. These data suggest
that autophosphorylation of CaMKII occurs and that the
regulation of CaMKII in vivo through phosphorylation/de-
phosphorylation is rapid.
Corresponding to the activation of CaMKII, OA and CL-A
increased phosphorylation of tau at Ser 262/356 as early as 10
min and the phosphorylated tau accumulated up to 60 min of
treatment studied (Figs. 1C,D and 3B,C). Hyperphosphoryla-
tion of tau was also observed in brain slices treated with OA,
CL-A and KN-62 (Fig. 3B,C). The total level of tau detected
by 92e was not signi¢cantly a¡ected by the combination of
di¡erent drugs used (Fig. 3B). These results con¢rm that hy-
perphosphorylation of tau is the result of the activation of
CaMKII. The addition of KN-62 in the presence of OA
and CL-A only produced a small reduction in the hyperphos-
phorylation of tau at Ser 262/356; the level of phosphoryla-
tion of tau by this treatment, although lower than in OA/CL-
A-treated rat brain slices, was signi¢cantly higher than control
tissue. These ¢ndings con¢rm that the activation of CaMKII
in rat brain tissue following treatment with OA and CL-A is
due to the inhibition of PP-2A/PP-1. Thus, PP-2A and PP-1
are the main phosphatases to dephosphorylate autophos-
phorylated CaMKII in brain tissue.
3.6. The cytosolic CaMKII activity in brain is regulated mainly
by PP-2A
In order to identify which of the two protein phosphatases
was responsible for the regulation of CaMKII activity in vivo,
we investigated the e¡ect of each protein phosphatase inhib-
itor separately. Rat brain slices were treated for 30 or 60 min
with OA and CL-A individually or in combination. CaMKII
was activated with either OA alone (which inhibited V65% of
PP-2A and produced no signi¢cant inhibition of PP-1, see
Table 1) or in combination with CL-A (Fig. 4). During 60
min, CaMKII activity remained stimulated with OA alone
although slightly lower than when both OA and CL-A were
used together. When rat brain slices were treated with CL-A
alone (which inhibited V50% of PP-1) for 30 min, CaMKII
activity was also upregulated although lower than when both
OA and CL-A were used (Fig. 4B). However, after 60 min
CaMKII activity in rat brain slices treated with only CL-A
was the same as in aCSF-treated control, whereas it remained
activated in the OA plus CL-A-treated sample. Since we em-
ployed 16 000Ug brain extract for assaying the CaMKII ac-
tivity, our results suggest that PP-2A upregulates the cytosolic
CaMKII activity.
The levels of tau phosphorylation at Ser 262/356 were the
same in the brain slices treated with OA or OA plus CL-A at
60 min (Fig. 4E). When CL-A was used alone V40% increase
Fig. 3. KN-62 together with OA and CL-A does not inhibit the
CaMKII activity stimulated by the phosphatase inhibitors and the
phosphorylation of tau at Ser 262/356. Rat brain slices were incu-
bated with aCSF (open bars), 1.0 WM OA and 0.1 WM CL-A (black
bars), and with a combination of 10 WM KN-62, 1.0 WM OA and
0.1 WM CL-A (striped bars). After treatment for 10, 20, 30 or 60
min, the brain slices were homogenized and centrifuged at 16 000Ug
for 20 min. (A) The CaMKII activity of inhibitors-treated samples
was expressed as the percentage of the activity of the control sample
treated with aCSF for the same period of incubation. KN-62, a spe-
ci¢c inhibitor of CaMKII, when used in combination with OA and
CL-A did not inhibit CaMKII activity. (B) Western blots of the
brain slices from A were developed with the mAb 12E8 (upper pan-
el; 10 Wg per lane) and the pAb 92e (lower panel; 5 Wg per lane).
KN-62, used in combination with OA and CL-A did not inhibit the
phosphorylation of tau at Ser 262/356. (C) Western blots such as in
B were scanned and the immunoreactivity obtained with 12E8 was
normalized against the level of total tau detected with the pAb 92e.
As expected, OA along with CL-A induced an increase of phos-
phorylation of tau Ser 262/356 (black bars) as opposed to aCSF-
treated samples (open bars). The use of KN-62 along with both OA
and CL-A resulted in hyperphosphorylation of tau at Ser 262/356
though the increase was lower than that obtained using OA plus
CL-A (striped bars). Data in A and C are presented as mean þ S.D.
of three experiments. *P6 0.05, **P6 0.01 between aCSF- and in-
hibitor-treated samples.
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in phosphorylation of tau at Ser 262/356 was observed where-
as as expected OA plus CL-A enhanced several fold the phos-
phorylation at this site (Fig. 4F). Thus, although CaMKII
was activated by 30 min treatment with CL-A (Fig. 4B), no
increase in phosphorylation of tau was observed at Ser 262/
356. In the OA-treated samples, the upregulation of CaMKII
activity (Fig. 4A) was correlated with the increase of tau phos-
phorylation at Ser 262/356 (Fig. 4C,E). Since CL-A only
slightly inhibited PP-2A activity (V20%) and this phospha-
tase dephosphorylated tau Ser 262/356, no major increase in
the phosphorylation was observed by treatment with this
drug. These ¢ndings suggest that the phosphorylation status
of tau protein at Ser 262/356 is probably the result of two
major mechanisms: a decrease in protein phosphatase 2A ac-
tivity and an increase in CaMKII activity. Thus, in vivo tau at
Ser 262/356 is a substrate for PP-2A and CaMKII, and CaM-
KII at Thr 286/287 itself is the substrate for PP-2A.
4. Discussion
OA and CL-A are the most studied cell permeable potent
inhibitors of PP-2A and PP-1. In cultured SY5Y cells, a treat-
ment with 10 nM OA for 24 h completely inhibited PP-2A
and V75% of the PP-1 activity [38]. However, unlike in vitro
and in cultured cells, maximally V70% inhibition of PP-2A
activity by 1.0^5.0 WM OA was observed in brain [40]. In the
present study, treatment of rat brain slices with 1.0 WM OA
resulted in V65% inhibition of PP-2A and no signi¢cant
change in PP-1 activity. Furthermore, unlike somewhat
known higher to Vequal a⁄nity of CL-A towards PP-2A
than PP-1 in vitro, in rat brain slices we observed V50%
inhibition of PP-1 and V20% inhibition PP-2A by 0.1 WM
CL-A. A combination of OA and CL-A practically completely
inhibited both PP-2A and PP-1 activities in rat brain slices
suggesting a synergistic e¡ect of the two inhibitors. These
studies demonstrated that the individual potency of OA and
CL-A to inhibit PP-2A/PP-1 activities in brain is not only
considerably less than that in vitro but also in the case of
CL-A its speci¢city towards PP-2A and PP-1 is somewhat
opposite. A complete inhibition of PP-2A and PP-1 activities
in brain observed by employing these two compounds in com-
bination is a promising new approach by which the role of
Fig. 4. The activity of cytosolic CaMKII is upregulated by both OA and calyculin. Rat brain slices were incubated for 30 min or 60 min in
either aCSF, 0.1 WM CL-A, 1.0 WM OA or both OA (1.0 WM) plus CL-A (0.1 WM) and the CaMKII activity and phosphorylation of tau at
Ser 262/356 determined as in Fig. 1. (A) OA alone or used in combination with CL-A increased CaMKII activity up to 200% in rat brain
tissue in 30 min. At 60 min CaMKII activity was signi¢cantly lower in OA-treated compared to OA/CL-A-treated tissue. Note that CaMKII
activity also decreased after 60 min of treatment with OA and CL-A. (B) CL-A alone stimulated CaMKII activity after 30 min of treatment.
Although increased, the activity was signi¢cantly lower than the CaMKII activity measured in rat brain treated with both OA and CL-A. At
60 min CaMKII activity in rat brain slices treated with CL-A alone was the same as the activity detected in aCSF-treated control tissue. (C^F)
Abnormal phosphorylation of tau at Ser 262/356 was detected when rat brain slices were treated with OA alone or in combination with CL-A.
In contrast, CL-A induced only a slight increase in the phosphorylation of tau at Ser 262/356. Data in A^F are presented as mean þ S.D. of
three experiments. *P6 0.05, **P6 0.01 as compared with the aCSF-treated samples (open bars).
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PP-2A/PP-1 can be investigated by the use of pharmacological
compounds. This approach is especially attractive because the
selective knock-out of PP-2A in transgenic mice is fatal [48].
In rat brain slices treated with protein phosphatase inhib-
itors, an increase of CaMKII activity was observed. CaMKII
activity was upregulated in rat brain after treatment with OA,
CL-A or both in combination. It is well known that CaMKII
activity is regulated by autophosphorylation and that auto-
phosphorylation at Thr 286/287 is necessary for full activation
of the activity [9^11]. Previous studies have reported that PP-
2A [7,17,18] and PP-1 [16] and PP-2C [19] dephosphorylate
autophosphorylated CaMKII. However, although the activity
of PP-2C has been reported to be present in the brain [1,49],
the localization of the mRNA showed that the enzyme was
mostly localized in the cerebellum [50]. PP-2B has been shown
to lack the capacity to dephosphorylate CaMKII [51]. Most
of these studies were conducted in vitro and autophosphory-
lation of CaMKII in vivo had not been elucidated. The
present study shows that cytosolic CaMKII in forebrain is
regulated primarily by PP-2A. Inhibition of PP-2A upregu-
lated CaMKII activity and brought its total activity to
2-fold as opposed to aCSF-treated rat brain slices. The inhi-
bition of V50% PP-1 by CL-A also increased CaMKII activ-
ity, however, markedly less than when V65% of PP-2A was
inhibited by OA.
CaMKII activity was associated with the increase in tau
phosphorylation at Ser 262/356 in rat brain. The use of the
speci¢c CaMKII inhibitor, KN-62, inhibited CaMKII activity
and no hyperphosphorylation at Ser 262/356 was then de-
tected. Moreover, the activity of PKA which also can phos-
phorylate tau at this particular site in vitro [27,28] was un-
a¡ected by the use of protein phosphatase inhibitors.
Although the role of other protein kinases in the phosphory-
lation of tau could not be ruled out, taken altogether our
results strongly suggest that CaMKII is the major mammalian
kinase to phosphorylate tau at Ser 262/356. In a recent study
we have shown that the treatment of the brain slices with OA
and CL-A not only inhibits PP-2A, PP-1 but also V80% of
GSK-3, V50% of cdk5 and V30% of cdc2 [33].
The increase in CaMKII activity was associated with an
increase in tau phosphorylation. However, in rat brain tissue
treated with CL-A for 30 min the upregulation of CaMKII
activity was not associated with any abnormal phosphoryla-
tion of tau at Ser 262/356. Since the treatment with CL-A for
30 min did not result in any signi¢cant inhibition of PP-2A,
tau at Ser 262/356 was probably dephosphorylated by this
phosphatase. Consistent with these ¢ndings, an V20% inhi-
bition of PP-2A produced by 60 min of treatment with CL-A
resulted in a small increase in the phosphorylation of tau at
Ser 262/356.
In conclusion, the present study suggests that in the fore-
brain PP-2A and to a lesser extent PP-1 downregulate the
activity of the cytosolic CaMKII probably by inhibiting its
autophosphorylation at Thr 286/287. Furthermore, tau at
Ser 262/356 is phosphorylated primarily by CaMKII and de-
phosphorylated by PP-2A. Thus, PP-2A regulates the activity
of CaMKII and both CaMKII and PP-2A regulate the phos-
phorylation of tau at Ser 262/356 in forebrain. A decrease in
PP-2A/PP-1 activities leads to the upregulation of CaMKII
activity and the phosphorylation of tau at Ser 262/356. The
decrease in PP-2A/PP-1 activities and the abnormal hyper-
phosphorylation of tau at Ser 262/356 in AD cerebral cortex
reported previously [1,52] might involve an increase in the
phosphorylation of tau by CaMKII and a decrease in the
dephosphorylation by PP-2A as shown in rat forebrain slices.
An increase in CaMKII immunocytochemical staining in hip-
pocampal pyramidal neurons in AD has been reported [53].
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